Nama's AI scorecard currently rates Omnicell Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is OMCL's P/E ratio?

Omnicell trades at a trailing price-to-earnings ratio of 15.1.

When does OMCL report earnings?

Omnicell's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $0.42.

What is the OMCL price target?

The median analyst price target from 7 analysts is $55.00, with a range of $50.00 – $68.00.

Is OMCL Shariah compliant?

Nama's AAOIFI-style screen reads Omnicell as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Omnicell (OMCL)

Healthcare · Health Information Services · NASDAQ

Omnicell (OMCL) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $1.72B, a trailing price-to-earnings ratio of 15.1 and a free-cash-flow yield of 4.0%. Over the most recent reported fiscal year, revenue grew 6.5% and free cash flow per share fell 48.7%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -1.5% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-80.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.72B
Trailing P/E	15.1
Price / book	1.3
Price / sales	1.4
FCF yield	4.0%
Dividend yield	—
Gross margin	44.8%
Operating margin	4.7%
Net margin	3.1%
Revenue growth (YoY)	+6.5%
Revenue growth (3-yr annual)	-2.9%
EPS growth (YoY)	-4.7%
FCF/share growth (YoY)	-48.7%
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Health Information Services

OMCL earnings

Next report: Feb 4, 2027 (Q4 2026, EPS estimate $0.42). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.58	$0.42	+38.1%	$307.85M
Q2 2026	Jul 30, 2026	$0.94	$0.47	+100.0%	$312.21M
Q1 2026	Apr 28, 2026	$0.55	$0.33	+66.7%	$309.88M
Q4 2025	Feb 5, 2026	$0.40	$0.50	-20.0%	$313.98M

OMCL analyst price target

Median target $55.00 from 7 analysts, ranging $50.00 – $68.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2

Explore live OMCL data on Nama Insights →

Recent Congressional trades

Omnicell trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas R Tillis	Senate	Sell	$1,001 - $15,000	—

OMCL FAQ

Is OMCL a buy?: Nama's AI scorecard currently rates Omnicell Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is OMCL's P/E ratio?: Omnicell trades at a trailing price-to-earnings ratio of 15.1.
When does OMCL report earnings?: Omnicell's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $0.42.
What is the OMCL price target?: The median analyst price target from 7 analysts is $55.00, with a range of $50.00 – $68.00.
Is OMCL Shariah compliant?: Nama's AAOIFI-style screen reads Omnicell as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.